Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy
- 889 Downloads
Goals of work
A number of prognostic factors have been identified as risk factors for chemotherapy-induced emesis. This post-hoc analysis addressed whether: (1) these prognostic factors can identify a low-risk group for whom ondansetron plus dexamethasone alone provide a high level of protection (≥80% no emesis); (2) the NK1 receptor antagonist aprepitant improves antiemetic outcome regardless of emetic risk.
Patients and methods
Breast cancer patients in a phase III double-blind, placebo-controlled trial were randomized to antiemetic regimens including ondansetron and dexamethasone, or aprepitant, ondansetron, and dexamethasone. Multivariate logistic regression models were used to assess the impact on emesis (but not nausea) of the regimen with aprepitant, and previously reported risk factors, including age (<55 and ≥55 years), ethanol use (0–4 or ≥5 drinks/week), history of pregnancy-related morning sickness, and history of motion sickness, using a modified intent-to-treat approach.
Treatment with aprepitant (P < 0.0001), older age (P = 0.006), ethanol use (P = 0.0048), and no history of morning sickness (P = 0.0007) were all significantly associated with reduced likelihood of emesis. The proportion of patients with one, two, or three risk factors who remained emesis free was significantly higher with the aprepitant-containing regimen than with the active control (70.2–82.8% vs. 38.6–66.4%, respectively).
Aprepitant markedly improved control of emesis in patients with one or more risk factors. This analysis did not support using risk factors for modifying the antiemetic approach. A low-risk group with zero risk factors for whom aprepitant provided little benefit was of questionable clinical utility, since they comprised less than 3% of patients.
KeywordsAprepitant Chemotherapy-induced nausea and vomiting Emesis Risk factor Anthracycline + cyclophosphamide
DGW is a consultant to Merck & Co.
JCS is a paid consultant to Merck & Co.
ADC is an employee of Merck & Co.
- 3.D′Acquisto R, Tyson LB, Gralla RJ (1986) The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. In: The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5:257Google Scholar
- 4.Hesketh PJ, Plagge P, Bryson JC (1992) Single-dose ondansetron for prevention of acute cisplatin-induced emesis: analysis of efficacy and prognostic factors. In: Bianchi AL, Grelot L, Miller AD (eds) Mechanisms and control of emesis. Libbey, LondonGoogle Scholar
- 8.Jordan K, Grothey A, Pelz T, Lautenschlager C, Franke U, Schober C et al (2009) Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting. Eur J Cancer Care (Engl) (in press)Google Scholar
- 9.Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112–4119PubMedCrossRefGoogle Scholar
- 10.Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098PubMedCrossRefGoogle Scholar
- 12.Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23(12):2822–2830PubMedCrossRefGoogle Scholar
- 13.Hesketh PJ, Aapro M, Street JC, Carides AD (2009) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase 3 trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer (in press)Google Scholar
- 15.National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology—V.3.2009: antiemesis. Available at www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed January 31, 2009.
- 17.Herrstedt J, Roila F (2008) Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 19(Suppl 2):i110–i112Google Scholar
- 18.Quality Oncology Practice Initiative Registration Surpasses 250 Oncology Practices: Spring 2007 Data Collection Provides Data to Drive Practitioner-Led Improvement (2009) J Oncol Pract 5:271–273Google Scholar
- 20.Walko CM, Yu YA, Bhushan S, Spasojevic I, Carey L, Collichio F et al (2009) Effect of aprepitant (AP) on cyclophosphamide (CPA) pharmacokinetics (PK) in early breast cancer patients. J Clin Oncol 27(15S May 20 Suppl)):588Google Scholar
- 23.Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5(4):307–313PubMedCrossRefGoogle Scholar